Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Diagnosis and Treatment of Parkinson Disease
JAMA 323:548-560, Armstrong, M.J. & Okun, M.S., 2020
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
A Meta-Regression of the Long-Term Effects of Deep Brain Stimulation on Balance and Gait in PD
Neurol 75:1292-1299, St. George,R.J.,et al, 2010
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Treatments of Parkinson Disease
Arch Neurol 60:1680-1684, Shults,C.W., 2003
Subthalamic DBS Replaces Levodopa in Parkinson's Disease
Neurol 58:396-401, Vingerhoets,F.J.G.,et al, 2002
Effects of Bilateral Subthalamic Nucleus Stimulation on Parkinsonian Gait
Neurol 57:144-146, Stolze,H.,et al, 2001
Axial Parkinsonian Symptoms Can Be Improved: The Role of Levodopa and Bilateral Subthalamic Stimulation
JNNP 68:595-600, Bejjani,B.P.,et al, 2000
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Parkinson's Disease
JNNP 57:672-681, Marsden,C.D., 1994
Suppression of"Rubral"Tremor with Levodopa
BMJ 281:1043, Findley,L.J.,et al, 1980
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Parkin Disease
JAMA Neurol 70:571-579, Doherty, K.,et al, 2013
Progressive Supranuclear Palsy: A Current Review
The Neurologist 14:79-88, Lubarsky,M. &Juncos,J.L., 2008
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
Dopamine-Responsive Dystonia
eMedicine (Apr), Nikhar,N.K., 2006
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Low-Dose Clozapine Improves Dyskinesias in Parkinson's Disease
Neurol 48:658-662, Durif,F.,et al, 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Neuroleptic Drug Exposure and Treatment of Parkinsonism in the Elderly:A Case-Control Study
Am J Med 99:48-54, Avorn,J.,et al, 1995
Multiple System Atrophy presenting as Parkinsonism:Clinical Features and Diagnostic Criteria
JNNP 59:144-151, Albanese,A.,et al, 1995
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Parkinsonism Induced by Solvent Abuse
Ann NEurol 35:616-618, Uitti,R.J.,et al, 1994
Early Development of Levodopa-Induced Dyskinesias and Response Fluctuations in Young-Onset Parkinson's Disease
Neurol 41:202-205, Kostic,V., 1991
The Dystonias
BMJ 300:139-144, Marsden,C.D.&Quinn,N.P., 1990
Levodopa-Induced Dyskinesia:Review, Observations, and Speculations
Neurol 40:340-345, Nutt,J.G., 1990
Decreased Efficacy of Levodopa with Carbidopa in Parkinsonian Patients after Adrenal-to-Caudate Implants
Neurol 40:845-846, Tsui,J.K.C.,et al, 1990
Neuroleptic-Induced Parkinson's Syndrome:Clinical Features and Results of Treatment with Levodopa
JNNP 51:850-854, Hardie,R.J.&Lees,A.J., 1988
Drug-induced Asterixis in Parkinson Disease
Neurol 32:553-555, Glantz,R.,et al, 1982
Onset & End-of-dose Levodopa-induced Dyskinesias
Arch Neurol 35:261, Lhermitte,F.,et al, 1978
Drug Therapy of Parkinsonism
NEJM 295:814, Bianchine,J.R., 1976
Catecholamines & Neurologic Diseases
NEJM 293:274, Moskowitz,M.A.,et al, 1975
Implications of Amphetamine-Induced Stereotyped Behavior as a Model for Tardive Dyskinesias
Arch Gen Psychiat 27:502-507, Rubovits,R.,et al, 1972
Drug-Induced Movement Disorders
Postgrad Med 180, 1971, Sept., North,R., 1971